Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Crushed and Ground Venetoclax in Healthy Females
NCT05909553Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of venetoclax in chronic lymphocytic leukemia (CLL) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Adverse Events up to 75 Days, Maximum Observed Plasma Concentration up to 45 Days and 5 more. Started Jun 2023; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05909553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909553.